Current Report · Items 2.02, 8.01, 9.01 · 8-K

Larimar Therapeutics, Inc.

LRMRNASDAQEQUITYCurrent

Results of Operations and Financial Condition · Other Events

Filed May 14, 2026Accepted May 14, 2026, 7:02 AM EDTCIK 1374690Accession 0001193125-26-222746

Company context

Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.

Current securities

LRMRNASDAQ · EQUITY · Current

Recent company filings

Disclosure sections

Items 2.02, 8.01, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations

Item 2.02 Results of Operations and Financial Condition. On May 14, 2026, Larimar Therapeutics, Inc. (the “Company”) announced its financial results and operational highlights for the first quarter ended March 31, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 8.01Item 8.01 - Other Events

Item 8.01 Other Events. On May 14, 2026, the Company posted on its website an updated slide presentation, which is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. Representatives of the Company will use the presentation in various meetings with investors, analysts and other parties from time to time.

Filed exhibits (2)

EX-99.1 (by filename) lrmr-ex99_1.htm

EX-99.1 2 lrmr-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Larimar Therapeutics Reports First Quarter 2026 Financial and Business Update • Intending to initiate rolling BLA seeking accelerated approval with submission of nonclinical and clinical modules in June 2026; submission of the final modules including the CMC module expected in second half of 2026 • Cross-species nonclinical findings that support skin frataxin levels as a surrogate endpoint for nomlabofusp program published in peer-reviewed journal • Topline open label study data to support BLA submission expected in Q2 2026 • $200.4 million in cash, cash equivalents and marketable securities as of March 31, 2026, with projected cash runway into the second quarter of 2027 Bala Cynwyd, PA, May 14, 2026 - Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its first quarter 2026 operating and financial results. “We have strong momentum as we advance nomlabofusp towards potential approval for the treatment of adults and children with Friedreich’s ataxia (FA). Our ongoing engagement with the U.S. Food and Dr…

Open exhibit ↗

EX-99.2 (by filename) lrmr-ex99_2.htm

EX-99.2 3 lrmr-ex99_2.htm EX-99.2 pro May 2026 Larimar Therapeutics Corporate Deck Exhibit 99.2 Forward-Looking Statements This presentation contains forward-looking statements that are based on Larimar’s management’s beliefs and assumptions and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including but not limited to statements regarding Larimar’s ability to develop and commercialize nomlabofusp and any other planned product candidates, Larimar’s planned research and development efforts, including the timing of its nomlabofusp clinical trials, interactions and filings with the FDA, expectations regarding the timing of the BLA submission, the expectations of the timing of, and potential for, accelerated approval or accelerated access, time to launch and market and overall development plans and other matters regarding Larimar’s business strategies, ability to raise capital, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words “ma…

Open exhibit ↗